Catalog No.
RMJ26601
Species reactivity
Mouse
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
Interleukin-31 receptor subunit alpha, IL-31 receptor subunit alpha, IL-31R subunit alpha, IL-31R-alpha, IL-31RA, GLM-R, mGLM-R, Gp130-like monocyte receptor, Gp130-like receptor, Novel cytokine receptor 10, NR10, ZcytoR17, Il31ra, Glmr
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8K5B1
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1987
Pre- and Postnatal Development Study of Nemolizumab, a Humanized Anti-Interleukin-31 Receptor A Monoclonal Antibody, in Cynomolgus Monkey., PMID:39868832
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs., PMID:38186219
Canine interleukin-31 binds directly to OSMRβ with higher binding affinity than to IL-31RA., PMID:37588794
[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis]., PMID:37121713
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis., PMID:36839897
IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin., PMID:36410530
Nemolizumab: First Approval., PMID:35834124
Nemolizumab for atopic dermatitis., PMID:35412530
Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis., PMID:34642338
Interleukin-31 and Pruritic Skin., PMID:33924978
Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues., PMID:33644104
Interleukin-31 as a Clinical Target for Pruritus Treatment., PMID:33644103
Increased expression of in situ IL-31RA and circulating CXCL8 and CCL2 in pemphigus herpetiformis suggests participation of the IL-31 family in the pathogenesis of the disease., PMID:32531145
Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA., PMID:32459958
IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis., PMID:31434203
IL-31 plays dual roles in lung inflammation in an OVA-induced murine asthma model., PMID:30647024
Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis., PMID:29524262
Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis., PMID:29248521
Regulation of Th2 responses by different cell types expressing the interleukin-31 receptor., PMID:28428802
The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment., PMID:28408397
Human basophils are a source of - and are differentially activated by - IL-31., PMID:28000952
Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody., PMID:27714851
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study., PMID:26409172
Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression., PMID:25847241
Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation., PMID:23694808
Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns., PMID:16926070
For research use only. Not for human or drug use.
